PedAM
Pediatric Disease Annotations & Medicines
| Disease | dementia |
| Phenotype | C0030567|parkinson\'s disease |
| Sentences | 137 |
| PubMedID- 21560084 | Recent genetic, neurochemical and neuropsychological experiments robustly confirm a link between dementia associated with parkinson's disease and dementia with lewy bodies. |
| PubMedID- 22219275 | Alpha-synuclein is a key molecule in the pathogenesis of synucleinopathy including dementia with lewy bodies, parkinson's disease, and multiple system atrophy. |
| PubMedID- 23119224 | Comprehensive neuropsychological data sets from a cohort of 121 parkinson's disease patients with and without dementia were explored by a factor analysis to characterize different cognitive domains. |
| PubMedID- 20522093 | Cognitive impairment and dementia associated with parkinson's disease (pd) are common and often have devastating effects upon the patient and their family. |
| PubMedID- 23610582 | [1],[2] rivastigmine is also indicated for patients with dementia associated with parkinson's disease (pd). |
| PubMedID- 25062696 | The neuropathological substrate of dementia in patients with parkinson's disease is still under debate, particularly in patients with insufficient alternate neuropathology for other degenerative dementias. |
| PubMedID- 20563819 | The synaptic pathology of alpha-synuclein aggregation in dementia with lewy bodies, parkinson's disease and parkinson's disease dementia. |
| PubMedID- 26117435 | Caregiver report of apathy predicts dementia in parkinson's disease. |
| PubMedID- 21596773 | The relative importance of lewy- and alzheimer-type pathologies to dementia in parkinson's disease remains unclear. |
| PubMedID- 20880750 | Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with parkinson's disease. |
| PubMedID- 26173861 | Mild cognitive impairment in parkinson's disease is associated with progression to dementia (parkinson's disease dementia) in a majority of patients. |
| PubMedID- 21437985 | Cognitive correlates of visual hallucinations in dementia associated with parkinson's disease. |
| PubMedID- 22862741 | Initial analysis of clinical csf samples of psp (n = 46), corticobasal syndrome (cbs; n = 22), ad (n = 11), parkinson's disease with dementia (pdd; n = 16) and 35 controls revealed selective decreases of immunoreactive 4r-tau in csf of psp and ad patients compared with controls, and lower 4r-tau levels in ad compared with pdd. |
| PubMedID- 23208306 | Spectroscopic changes associated with mild cognitive impairment and dementia in parkinson's disease. |
| PubMedID- 21370709 | Tackling dementia in patients with parkinson's disease. |
| PubMedID- 21072963 | When a diagnosis of alzheimer's disease, ad with cerebrovascular disease or with lewy body disease, or dementia associated with parkinson's disease or lbd is made, evidence based medical therapy is indicated as part of comprehensive care. |
| PubMedID- 22595371 | After the subsequent findings of markedly reduced tracer reuptake in the basal ganglia on [123i]fp-cit dat images, a diagnosis of parkinson's disease with dementia was made when he was in his early 50s. |
| PubMedID- 22577599 | dementia in parkinson's disease correlates with alpha-synuclein pathology but not with cortical astrogliosis. |
| PubMedID- 25273524 | Education-corrected cerad identifies mci and dementia in parkinson's disease. |
| PubMedID- 23691698 | The prevalence and the associated factors of dementia in patients with parkinson's disease at maharat nakhon ratchasima hospital. |
| PubMedID- 22042172 | To determine the prevalence of dementia associated with parkinson's disease (pd-d) in a brazilian sample adopting clinical and diagnostic procedures recommended by the movement disorders society (mds). |
| PubMedID- 24464490 | Treatment of psychosis and dementia in parkinson's disease. |
| PubMedID- 20187235 | Cognitive impairment and dementia in parkinson's disease. |
| PubMedID- 23271313 | Retinal nerve fiber layer thinning in dementia associated with parkinson's disease, dementia with lewy bodies, and alzheimer's disease. |
| PubMedID- 26541556 | The cross-sectional and longitudinal relationships between white matter hyperintensities and dementia in patients with parkinson's disease: a retrospective analysis of 132 patients in a single center. |
| PubMedID- 20522088 | The epidemiology of dementia associated with parkinson's disease. |
| PubMedID- 24296865 | dementia in parkinson's disease (pd) is a serious health issue and a major concern for many patients. |
| PubMedID- 23111294 | As the population of many countries ages, disorders of cognition and memory-such as alzheimer's disease (ad) and dementia associated with parkinson's disease-will become a major societal burden. |
| PubMedID- 20428976 | dementia associated with parkinson's disease (pdd) is a common problem and one that is associated with significant morbidity and mortality. |
| PubMedID- 22806065 | Despite the frequency and importance of dementia associated with parkinson's disease (pdd) and dementia with lewy bodies (dlb), there is relatively little evidence on which to base treatment. |
| PubMedID- 20523050 | Aims: to investigate the effects of rivastigmine capsule 3-12 mg/day over 24 weeks on activities of daily living (adls) in patients with dementia associated with parkinson's disease (pdd). |
| PubMedID- 23843893 | For example, in ad patients, tpso pet enabled the discovery of the relationship between aβ accumulation and microglia activation during disease process 152 and can detect an age related increase in microglia activation in normal human brains and in ad progression 153. however, based on current research, no definite conclusion can be drawn between the results of amyloid plaque imaging using 11c-pib and inflammation imaging targeting tpso 53, 154, 155. microglia activation was found to be a potential driving force in the development of parkinson's disease with dementia (pdd) and could be detected via tpso pet at the early phase in pd patients 156. in stroke, tspo pet imaging was able to find the temporal dynamics of microglia activation in patients, which was correlated with clinical outcome 157. in traumatic brain injury (tbi), the imaging of microglia via tspo was found to be present up to 17 years after tbi, indicating the possible benefit of long-term interventions for post-tbi patients 158. however, some discrepancies exist among different studies, and this might be due to the lack of standardized analysis of imaging results and certain limitations of radiotracer for pet neuroinflammation imaging, such as low binding affinity and low target-to-background ratio 159. therefore, the development of new tracers with better imaging properties and the improvement in quantitative data analysis should be of great importance for pet guided neuroinflammation imaging in the future. |
| PubMedID- 24376773 | More recently, cerebrospinal fluid (csf) concentrations of aβ peptides have been widely used to study alzheimer's disease pathology in vivo and their utility to diagnose parkinson's disease with dementia is under evaluation [32]. |
| PubMedID- 22419314 | Cholinesterase inhibitors for dementia with lewy bodies, parkinson's disease dementia and cognitive impairment in parkinson's disease. |
| PubMedID- 25887557 | Clonidine has been studied in outpatients with alzheimer's dementia [46,47] and in patients with parkinson's disease [48,49]. |
| PubMedID- 21915906 | In additional cox models, parkinson's disease patients with dementia had particularly high risks of mortality (adjusted hazard ratio, 2.62; 95% ci, 1.40-4.90; p < .001). |
| PubMedID- 26294137 | parkinson's disease (pd) with dementia and falls is improved by achei. |
| PubMedID- 24356537 | Early diagnosis of alzheimer's disease and parkinson's disease associated with dementia using cerebral perfusion spect. |
| PubMedID- 20064549 | Emotional changes, impairment of object recognition, and neuroinflammation are seen in parkinson's disease with dementia (pdd). |
| PubMedID- 24685119 | Like ace, moca are useful to detect dementia with parkinson's disease, and for more detailed testing for those scoring relatively highly in shorter cognitive tests. |
| PubMedID- 25206566 | These data suggest that cortical atrophy is a substrate for dementia in parkinson's disease. |
| PubMedID- 21684792 | dementia associated with parkinson's disease: applying the movement disorder society task force criteria. |
| PubMedID- 23551405 | Background: rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate alzheimer's disease (ad) and dementia associated with parkinson's disease. |
| PubMedID- 26275564 | C9orf72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or parkinson's disease complicated by psychosis or dementia in a sardinian population. |
| PubMedID- 23955613 | Is neuroinflammation involved in the development of dementia in patients with parkinson's disease. |
| PubMedID- 21442661 | Gray matter atrophy was greater in parkinson's disease with dementia, with similar change over time in both parkinson's disease and parkinson's disease with dementia. |
| PubMedID- 24123241 | The level i algorithm for the diagnosis of dementia associated with parkinson's disease (pd-d) recommended by the movement disorder society task force includes a pill questionnaire to determine the impact of cognitive decline on daily activities. |
| PubMedID- 25024059 | Objective: aim of this study was to identify risk factors for the development of dementia in patients with parkinson's disease (pd). |
| PubMedID- 22287381 | We also found an association between severe hyposmia and a characteristic distribution of cerebral metabolic decline, which was identical to that of dementia associated with parkinson's disease. |
| PubMedID- 22484304 | Cognitive impairment and dementia in parkinson's disease. |